Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population

Garcia, 2018, Diagnosis and management of the antiphospholipid syndrome, N. Engl. J. Med., 378, 2010, 10.1056/NEJMra1705454

Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb. Haemost., 4, 295, 10.1111/j.1538-7836.2006.01753.x

Gomez-Puerta, 2014, Diagnosis and classification of the antiphospholipid syndrome, J. Autoimmun., 48–49, 20, 10.1016/j.jaut.2014.01.006

Love, 1990, Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance, Ann. Intern. Med., 112, 682, 10.7326/0003-4819-112-9-682

Bowman, 2015, Prevalence of antiphospholipid antibodies and risk of subsequent adverse obstetric outcomes in women with prior pregnancy loss, J. Reprod. Immunol., 107, 59, 10.1016/j.jri.2014.09.052

Vinatier, 2001, Antiphospholipid syndrome and recurrent miscarriages, Eur. J. Obstet. Gynecol. Reprod. Biol., 96, 37, 10.1016/S0301-2115(00)00404-8

McIntyre, 2003, Frequency and specificities of antiphospholipid antibodies (aPL) in volunteer blood donors, Immunobiology, 207, 59, 10.1078/0171-2985-00210

Pengo, 2016, APS - diagnostics and challenges for the future, Autoimmun. Rev., 10.1016/j.autrev.2016.07.028

Fabris, 2014, The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation, Auto Immun. Highlight., 5, 63, 10.1007/s13317-014-0061-3

Arachchillage, 2013, Use of new oral anticoagulants in antiphospholipid syndrome, Curr. Rheumatol. Rep., 15, 331, 10.1007/s11926-013-0331-5

Meroni, 2018, Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?, Nat. Rev. Rheumatol., 14, 433, 10.1038/s41584-018-0032-6

Bor, 2018, Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-beta2-glycoprotein I antibodies: a systematic evaluation according to the guidelines, Lupus, 27, 1446, 10.1177/0961203318776105

Lakos, 2012, International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies, Arthritis Rheum., 64, 1, 10.1002/art.33349

Bertolaccini, 2014, 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends, Autoimmun. Rev., 13, 917, 10.1016/j.autrev.2014.05.001

Baldassarre, 2012, J. Am. Coll. Cardiol., 60, 1489, 10.1016/j.jacc.2012.06.034

Lloyd-Jones, 2006, Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age, Circulation, 113, 791, 10.1161/CIRCULATIONAHA.105.548206

Meschia, 2000, vol. 34, 119

Muka, 2016, Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis, JAMA Cardiol., 1, 767, 10.1001/jamacardio.2016.2415

Halcox, 2014, C-reactive protein levels in patients at cardiovascular risk: EURIKA study, BMC Cardiovasc. Disord., 14, 25, 10.1186/1471-2261-14-25

Nelson, 2013, Hyperlipidemia as a risk factor for cardiovascular disease, Prim Care, 40, 195, 10.1016/j.pop.2012.11.003

Kang, 2018, Analytic approaches for the treatment of hyperhomocysteinemia and its impact on vascular disease, Cardiovasc. Drugs Ther., 32, 233, 10.1007/s10557-018-6790-1

D'Agostino, 2008, General cardiovascular risk profile for use in primary care: the framingham heart study, Circulation, 117, 743, 10.1161/CIRCULATIONAHA.107.699579

Mortensen, 2017, ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the copenhagen general population study, Eur. Heart J., 38, 586

Mortensen, 2017, Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention, Eur. Heart J., 38, 2259

Xie, 2014, Homocysteine induces procoagulant activity of red blood cells via phosphatidylserine exposure and microparticles generation, Amino Acids, 46, 1997, 10.1007/s00726-014-1755-6

Kam, 2012, Combination of TNF-alpha, homocysteine and adenosine exacerbated cytotoxicity in human cardiovascular and cerebrovascular endothelial cells, Cell. Physiol. Biochem., 30, 805, 10.1159/000341459

Belizna, 2008, Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding, Semin. Arthritis Rheum., 37, 373, 10.1016/j.semarthrit.2007.08.002

Medina, 2003, Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome, Ann. Rheum. Dis., 62, 607, 10.1136/ard.62.7.607

Der, 2007, Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome, Lupus, 16, 497, 10.1177/0961203307080224

Margarita, 2007, Subclinical atherosclerosis in primary antiphospholipid syndrome, Ann. N. Y. Acad. Sci., 1108, 475, 10.1196/annals.1422.050

Jimenez, 2005, Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome, Rheumatology, 44, 756, 10.1093/rheumatology/keh581

Bilora, 2002, Are antiphospholipid antibodies an independent risk factor for atherosclerosis?, Clin. Appl. Thromb. Hemost., 8, 103, 10.1177/107602960200800205

Matsuura, 2006, Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis, Prog. Lipid Res., 45, 466, 10.1016/j.plipres.2006.05.001

George, 1997, Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies, Lupus, 6, 723, 10.1177/096120339700600908

Wu, 1999, Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus, Clin. Exp. Immunol., 115, 561, 10.1046/j.1365-2249.1999.00830.x

Ambrosino, 2014, Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies, Ann. Med., 46, 693, 10.3109/07853890.2014.959559

Di Minno, 2019, Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: a cross-sectional study, Int. J. Cardiol., 274, 1, 10.1016/j.ijcard.2018.06.010

Selmi, 2016, Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years, Autoimmun. Rev., 15, 162, 10.1016/j.autrev.2015.10.007

Selmi, 2019, Sex and autoimmunity: proposed mechanisms of disease onset and severity, Expert Rev. Clin. Immunol., 15, 607, 10.1080/1744666X.2019.1606714